Alnylam stock maintains Buy rating at H.C. Wainwright after strong Q3 results
PositiveFinancial Markets

Alnylam Pharmaceuticals has received a 'Buy' rating from H.C. Wainwright following impressive third-quarter results. This endorsement highlights the company's strong performance and growth potential, making it an attractive option for investors. The positive outlook reflects confidence in Alnylam's innovative therapies and market position, which could lead to further advancements in the biotech sector.
— Curated by the World Pulse Now AI Editorial System









